AVITA Medical raises full-year sales forecast to $92m-$94m on strong quarter

AVITA Medical reported third-quarter 2026 revenue of $26.1m on 5 November, up 53% on the comparable period. The company, which sells the RECELL skin-regeneration system alongside the Cohealyx and PermeaDerm wound products, also raised its expectation for 2026 sales to between $92m and $94m.

The balance-sheet news was as notable as the sales. AVITA has taken the final $10m instalment of its credit facility with Perceptive Advisors, so the loan is now fully drawn. It also removed the going-concern qualification, the formal statement that there is substantial doubt about a company's ability to keep operating over the next year. The material provided does not say what drove the removal or give the total size of the facility.

On reimbursement, the US Centers for Medicare & Medicaid Services (CMS) has finalised physician payment values for RECELL procedures and simplified the associated billing codes. The changes take effect on 1 January 2027. The payment amounts and the specific codes affected were not disclosed in the information available to CompePharma.

The material provides no product-level revenue split, no profit or cash figures, and no detail on how the guidance range was built, so the sources of growth cannot be broken down.